CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 2.29 and has seen 1,450,195 shares traded in the last trading session. The company, currently valued at $9.79 Billion, closed the last trade at $129.77 per share which meant it lost -$0.48 on the day or -0.37% during that session. The CRSP stock price is -69.68% off its 52-week high price of $220.2 and 75.11% above the 52-week low of $32.3. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.52 Million shares traded. The 3-month trading volume is 2.42 Million shares.
The consensus among analysts is that CRISPR Therapeutics AG (CRSP) is an Overweight stock at the moment, with a recommendation rating of 2.4. 1 analysts rate the stock as a Sell, while none rate it as Overweight. 7 out of 18 have rated it as a Hold, with 10 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$1.49.
Despite being -0.37% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Feb 24 when the CRSP stock price touched $139 or saw a rise of 6.64%. Year-to-date, CRISPR Therapeutics AG shares have moved -15.24%, while the 5-day performance has seen it change -4.09%. Over the past 30 days, the shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have changed -22.82%. Short interest in the company has seen 3.05 Million shares shorted with days to cover at 1.26.
Wall Street analysts have a consensus price target for the stock at $157.87, which means that the shares’ value could jump 21.65% from current levels. The projected low price target is $52 while the price target rests at a high of $210. In that case, then, we find that the current price level is +61.82% off the targeted high while a plunge would see the stock lose -59.93% from current levels.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Figures show that CRISPR Therapeutics AG shares have underperformed across the wider relevant industry. The company’s shares have gained +43.06% over the past 6 months, with this year growth rate of 10.4%, compared to 11.3% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -29.6% and -17.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be +1375.7%.
14 analysts offering their estimates for the company have set an average revenue estimate of $1.28 Million for the current quarter. 14 have an estimated revenue figure of $1.3 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $3.04 Million and $18.12 Million respectively for this quarter and the next, and analysts expect sales will grow by -57.9% for the current quarter and -92.8% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -52.5% over the past 5 years. Earnings growth for 2021 is a modest -550.5%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Insiders own 13.71% of the company shares, while shares held by institutions stand at 68.49% with a share float percentage of 79.38%. Investors are also buoyed by the number of investors in a company, with CRISPR Therapeutics AG having a total of 405 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 10.41 Million shares worth more than $1.59 Billion. As of December 30, 2020, ARK Investment Management, LLC held 13.81% of shares outstanding.
The other major institutional holder is Capital International Investors, with the holding of over 7.43 Million shares as of December 30, 2020. The firm’s total holdings are worth over $1.14 Billion and represent 9.85% of shares outstanding.